Trial
NCT04220411
A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Arjil Pharmaceuticals LLC
Collaborators
—
Condition
Dermatitis, Atopic
Intervention
AR100DP1
Why stopped
Due to the two AEs in Phase IIa study, recruiting was stopped for safety sake. The study was currently terminated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-11